Get the Weekly Intelligence Brief — top committee picks every Sunday.
NASDAQ · STOCK

McKesson Corporation

MCK Healthcare Unknown Updated July 31, 2026
$856.25
52W $637.00 – $999.00
57/100
$100.24B
22.2
0.32
AI Committee Verdict
Watch
Conviction: Contested · 57% agreement · 7 analysts
+4.6%
-7.7%
0.59:1
Contested

Is MCK Bullish or Bearish?

Mixed. Innellis AI committee rates McKesson Corporation (MCK) Watch with a composite score of 57/100 , based on 7 analysts with 57% agreement. Last updated July 31, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +2.85 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -17.15 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Growth Analyst sees a compelling case — eps growing 48.9% yoy. Risk Analyst remains cautious — current ratio of 0.85 is tight -- limited short-term liquidity cushion. This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • ROE of 39.4% shows genuine earnings power backing the valuation — Value
  • EPS growing 48.9% YoY — Growth
  • 4 consecutive earnings beats -- consistent execution — Growth
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • MACD histogram positive -- bullish momentum — Technical
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
  • Price-to-book of 4.3x prices in significant intangible value — Value
  • Current ratio of 0.85 is tight -- limited short-term liquidity cushion — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of July 31, 2026
Overall Committee Score
57/100
Agreement
57%
Analysts
7
Conviction
Contested
Sector Rank
Top 35%
of 93 Healthcare peers
Value Analyst neutral
55 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 39.4% shows genuine earnings power backing the valuation
− Price-to-book of 4.3x prices in significant intangible value
Growth Analyst bullish
79 / 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 48.9% YoY
Technical Analyst neutral
58 / 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
Risk Analyst bearish
35 / 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Current ratio of 0.85 is tight -- limited short-term liquidity cushion
Macro Analyst neutral
58 / 100 · Moderate confidence
Macro backdrop is mixed or neutral -- not a strong tailwind or headwind either way
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst bullish
70 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.40 across 37 articles, 14d)
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2744.14)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 56.2 to 57.1.

Analyst-level changes:
  • Macro Analyst: stance bullish->neutral; score 65->58 (-8); +1 bullish signal(s).
  • News Analyst: score 66->70 (+4); +1 bullish signal(s).
  • Portfolio Manager: +2 bearish signal(s).
  • Technical Analyst: score 48->58 (+10).

Comparing 2026-07-30 to 2026-07-31 (1 day apart).

Technical Analysis

RSI (14)
56.8
Neutral
MACD Histogram
3.647
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Support
$789.96
Resistance
$895.45
Bollinger %B
0.72
Inside Bands
Price vs Moving Averages
EMA 9
$854.27 Above
EMA 21
$831.56 Above
EMA 50
$811.94 Above
EMA 200
$810.65 Above

Fundamental Analysis

Valuation
90
Growth
84
Profitability
0
Financial Health
52
Cash Flow
37
Valuation
P/E Ratio 22.2×
P/B Ratio -48.13×
PEG Ratio 0.45
Dividend Yield 0.00%
52W High $999.00
52W Low $637.00
Quality & Growth
ROE -219.2%
ROA 5.8%
Gross Margin 3.6%
Operating Margin 1.6%
Revenue Growth YoY
Debt / Equity -3.97
AI Fundamental Assessment
P/E ratio of 22.2 (inexpensive relative to a 15-40x range); Price-to-book of -48.1x; PEG ratio of 0.5 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -2.2%; Return on assets of 0.1%; Net margin of 0.0%; Gross margin of 0.0%; Current ratio of 0.85 (tight short-term liquidity); Debt-to-equity of -3.97; Free cash flow margin of 1.0% (thin cash generation); Free cash flow per share is positive (48.62); Most recent quarter beat estimates by 0.1%; 4 consecutive earnings beats; EPS growth accelerating (-5.3% -> +25.2% QoQ); Analyst estimates rising over recent quarters
Get the Full MCK Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore MCK Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime